Login / Register

Username:


Password: [Lost?]



New User? Click here for your FREE subscription



Physical Therapists & PT Assistants
Physical Therapists & PT Assistants Physical Therapists & PT Assistants

Follow Us


NEWS-Line on Twitter NEWS-Line on Facebook NEWS-Line on Google+ NEWS-Line on LinkedIn NEWS-Line on Pinterest


Physical Therapist Conferences &
Educational Opportunities




Oct. 9 - 12

Annual Meeting

APTA

More Events

Established Drug For Symptoms Of Angina Pectoris Also Protects Vascular System | NEWS-Line for Physical Therapists & PT Assistants
 


Established Drug For Symptoms Of Angina Pectoris Also Protects Vascular System


Source:

A drug used in the clinical treatment of angina symptoms also has an anti-inflammatory effect and reduces atherosclerotic plaques in blood vessels - thereby reducing the risk of heart attack or stroke. The study, led by MedUni Vienna and including access to data from Harvard Medical School, has now been published in the highly regarded journal "PNAS".

The complications of atherosclerosis – heart attack and stroke – are the leading causes of death in Europe and the United States. In recent years, it has been shown that chronic inflammation in the arteries leads to the formation and progression of atherosclerotic plaques (deposits in the blood vessels). The MedUni Vienna research group led by Walter Speidl (Department of Medicine II, Division of Cardiology) and Philipp Hohensinner (Center for Biomedical Research) has now demonstrated for the first time that a reduction in intracellular sodium concentration inhibits the important inflammatory modulator NF-kappa-B. The drug ranolazine is a long-established drug used to relieve the symptoms of angina pectoris. However, it also inhibits the uptake of sodium into cells.

Johann Wojta, Head of the Cardiology Research Laboratory at the Medical University of Vienna, and co-author of the study explains: "In this publication, we used research involving cell culture, animal models and a large-scale human study to identify a new mechanism for inhibiting inflammation in atherosclerosis. We now have evidence that an established drug not only combats the symptoms of angina but can also reduce the risk of heart attack and stroke."

Using data provided by Harvard Medical School, this anti-inflammatory effect was demonstrated in 6,500 patients who had suffered myocardial infarction. It was found that treatment with ranolazine results in lower levels of the inflammatory and cardiovascular risk marker "high-sensitivity C-reactive protein" compared to placebo. Max Lenz, lead author of the study says: "We have now been able to show that ranolazine is not only effective against symptoms. It has an anti-inflammatory effect and reduces atherosclerotic plaques in our mouse models. These plaques also become more stable, potentially significantly reducing the risk of heart attack." Ranolazine is thus a safe drug that has already been approved for patients with coronary heart disease and leads to a reduction in chronic vascular inflammation.

Publication: Proceedings of the National Academy of Sciences (PNAS)
Pharmacologic modulation of intracellular Na+ concentration with ranolazine impacts inflammatory response in humans and mice.
Max Lenz, Manuel Salzmann, Cosmin I. Ciotu, Christoph Kaun, Konstantin A., Krychtiuk, Andreja Rehberger, Miran Sebestjen, Laura Goederle, Sabine Rauscher, Zoriza Krivaja, Christoph J. Binder, Kurt Huber, Christian Hengstenberg, Bruno K. Podesser, Michael J.M. Fischer, Johann Wojta, Philipp J. Hohensinner, Walter S. Speidl
Doi: 10.1073/pnas.2207020119
https://www.pnas.org/cgi/doi/10.1073/pnas.2207020119

Medical University Vienna (MedUni Vienna) is one of the most traditional medical education and research facilities in Europe. With almost 8,000 students, it is currently the largest medical training centre in the German-speaking countries. With 6,000 employees, 30 departments and two clinical institutes, 13 medical theory centres and numerous highly specialised laboratories, it is also one of Europe's leading research establishments in the biomedical sector.

Source: Medical University of Vienna






Share This!


Physical Therapist Jobs


Physical and Occupational Therapists & Speech Language Pathologist

Wellington Healthcare Services
Georgia

Physical and Occupational Therapists & Speech Language Pathologist

Wellington Healthcare Services
Louisiana

Physical Therapist, Clinical,

The Arc of Union County
Union County, New Jersey

Physical Therapist - full/part time - Early Childhood Intervention (ECI) (0-3 years) program

Dallas Center
Dallas, Texas

Physical Therapist - New Grads and Part Timers Welcome to Apply,

SCOR Physical Therapy
San Clemente, California

Physical Therapist - Outpatient Orthopedic Practice - $5,000 Sign-on bonus

Elite Physical Therapy & Wellness Center
Washington (beautiful Upper Georgetown/Glover Park area) , District of Columbia

More Jobs
(Dismiss) Thank you for visiting NEWS-Line! Please sign up, login, or follow us on your favorite social networks
to receive custom tailored eNews, job listings, and educational opportunities for your specific profession.